How much could a $10,000 investment in these ASX 200 stocks be worth if they hit 12 month targets?

Is now the ideal time to buy these beaten down ASX 200 stocks?

| More on:
A woman is very excited about something she's just seen on her computer, clenching her fists and smiling broadly.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here at The Motley Fool, we are always looking to identify S&P/ASX 200 Index (ASX: XJO) stocks that could be undervalued.

Three that have been hotly covered in recent weeks are Pro Medicus Ltd (ASX: PME), REA Group Ltd (ASX: REA) and Nextdc Ltd (ASX: NXT). 

These ASX 200 stocks are either sitting close to 52-week lows, or far from yearly highs.

However for all three, it looks like there could be greener pastures ahead. 

Based on recent price targets from analysts, let's look at just how profitable they could be as a value investment over the next 12 months. 

Pro Medicus Ltd (ASX: PME)

Pro Medicus provides medical imaging technology globally. 

It is the ASX 200's fifth-largest company.

The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

Yesterday, Pro Medicus shares closed at $177.56. 

This is a 37% drop over the last 12 months. 

However there is plenty of long-term potential for this ASX 200 stock. 

In its FY25 result, the company reported revenue growth of 31.9% to $213 million and net profit after tax (NPAT) growth of 39.2% to $115.2 million.

With strong fundamentals, low operating costs and a dominant market presence, I think it's a matter of "when" not "if" this stock bounces back. 

A recent rating from Macquarie included an outperform rating and price target of $291.30. 

Should Pro Medicus shares hit this target in the next 12 months, a $10,000 investment would turn into approximately $16,409.

REA Group Ltd (ASX: REA)

REA Group shares have been heavily sold over the last year, likely due to AI concerns and competition worries.

But while investors have been exiting the stock, experts remain steadfast in their confidence. 

Yesterday, REA Group shares closed at $191.60 each. 

This is hovering close to yearly lows, with the ASX 200 stock down almost 23% in the last 12 months. 

The Motley Fool's Tristan Harrison reported earlier this week that the team at UBS sees UBS an economic moat in customer experience, brand, uniqueness of product and complexity of the ecosystem. 

The broker also said the negative AI narrative could unwind over this year.

UBS has a price target of $255 on REA Group shares. 

If this ASX 200 stock were to hit that target in the next year, a $10,000 investment would grow to approximately $13,308. 

Nextdc Ltd (ASX: NXT)

This ASX 200 stock has also been hotly covered due to its perceived value and connection with the AI trend.

The company operates data centres in Australia, New Zealand and Southeast Asia. It focuses on co-location services to local and international organisations as well as interconnectivity between enterprises, global cloud, ICT providers, and telecommunication networks.

While it has fought back considerably from 52-week lows, estimates from brokers indicates the current price is still a value play. 

NextDC shares closed yesterday at $13.26 each. 

However, Ord Minnett has a buy recommendation and a $20.50 target price on this ASX 200 stock. 

If it hit that target in a year, a $10,000 investment would grow to be worth approximately $15,460. 

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Buy and sell written on a white cube.
52-Week Lows

3 ASX 200 shares worth buying after February's sell-off

February’s sell-off has dragged several ASX 200 growth shares back to more attractive levels.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Blue Chip Shares

Ord Minnett has a 'strongly positive view' on this ASX 200 star

The broker has good things to say about this blue chip.

Read more »

A warehouse worker is standing next to a shelf and using a digital tablet.
Retail Shares

Are Wesfarmers shares a buy for passive income?

The outlook for the blue-chip stock is solid, but far from spectacular.

Read more »

A woman standing on the street looks through binoculars.
Blue Chip Shares

Which ASX shares benefit from a stronger AUD?

Where should investors look with a strengthening AUD?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Blue Chip Shares

3 fantastic ASX 200 blue chip shares to buy with $5,000

These big-names are highly rated by analysts. But why?

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
Blue Chip Shares

Instead of Westpac shares, I would buy these ASX blue chips

For new money, I’d rather back established businesses with clearer growth runways than rely on the domestic banking cycle.

Read more »

Man presses green buy button and red sell button on a graph.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These two investments offer blue-chip exposure and big yields.

Read more »

Macquarie shre price asx share price opportunity represented by road sign saying opportunity ahead
Blue Chip Shares

3 ASX 200 shares I would buy in February

Here's 3 quality ASX 200 shares to watch this month as market conditions shift.

Read more »